Haisco Pharmaceutical expanded its newco strategy by launching Sentivera and initiating a high-value licensing effort tied to oral therapies for inflammatory diseases. Sentivera was formed through investments led by ARCH Venture Partners and Population Health Partners around an undisclosed preclinical immunology asset. The deal structure is framed as a competitor-building move toward oral, type 2 inflammatory disease programs. Coverage also describes Haisco licensing inflammatory disease drug rights to Sentivera, with Sentivera positioned as the US-facing development vehicle. Separately, reporting indicates Sentivera’s emergence is anchored to a $1.5 billion deal range, underscoring how quickly new ventures are being capitalized to secure late-stage development pathways. For the industry, the activity signals continued build-out of next-generation oral immunology pipelines outside established big-pharma franchises.